Pepe J, Cipriani C, Cantatore F P, Fabbri A, Pola E, Vinicola V, Raimo O, Biamonte F, Pascone R, Ferrara C, Minisola S
Department of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Rheumatology Unit, University of Foggia, Foggia, Italy.
J Endocrinol Invest. 2017 Jun;40(6):663-667. doi: 10.1007/s40618-017-0636-8. Epub 2017 Feb 25.
To investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis.
Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study.
At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94).
PTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.
研究18个月甲状旁腺激素1-84（PTH 1-84）治疗对已确诊骨质疏松症的绝经后女性血清骨形态发生蛋白4（BMP4）和血管内皮生长因子（VEGF）水平的影响。
纳入37例绝经后骨质疏松症女性（平均年龄72.9±8.1岁）和23例健康对照者（平均年龄68.9±9.9岁）。患者每日皮下注射100微克PTH（1-84），持续18个月，同时每日口服1克钙和800国际单位维生素D。研究期间每6个月采集一次血样。
基线时，患者和对照者在人体测量参数、合并症、当前使用药物方面无差异。骨质疏松症患者的平均血清VEGF水平显著高于对照者（436.7±259.7 vs. 260.3±184.3皮克/毫升，p = 0.006），而BMP4的平均血清值无差异（5.3±1.7 vs. 5.7±1.6皮克/毫升，p = 0.40）。与基线相比，PTH（1-84）治疗12个月后血清VEGF水平升高约20%（p = 0.03），18个月后升高22%（p = 0.01）。与基线相比，PTH（1-84）治疗18个月后平均血清BMP4水平显著升高10%（p = 0.02）。在对照组中，18个月后与基线相比，BMP4（5.7±1.6 vs. 6.0±1.5皮克/毫升，p = 0.53）和VEGF（260.3±184.3 vs. 257.4±107.1皮克/毫升，p = 0.94）无差异。
PTH（1-84）治疗可提高重度骨质疏松症绝经后女性的血清VEGF和BMP4水平。
